AXGN

SEC source: 0000805928-24-000049 · wk-form4_1711417219.xml · nonDerivative · entry 2

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,661

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-24-000047 · wk-form4_1711417017.xml · nonDerivative · entry 6

Scopelianos Angelo · CIK 0001751541 · Chief R&D Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,994

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-24-000047 · wk-form4_1711417017.xml · nonDerivative · entry 5

Scopelianos Angelo · CIK 0001751541 · Chief R&D Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,604

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2024.

SEC source: 0000805928-24-000047 · wk-form4_1711417017.xml · nonDerivative · entry 4

Scopelianos Angelo · CIK 0001751541 · Chief R&D Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,104

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-24-000047 · wk-form4_1711417017.xml · nonDerivative · entry 2

Scopelianos Angelo · CIK 0001751541 · Chief R&D Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,999

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-24-000044 · wk-form4_1711416165.xml · nonDerivative · entry 6

Donovan Michael Patrick · CIK 0001653918 · VP Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,250

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-24-000044 · wk-form4_1711416165.xml · nonDerivative · entry 4

Donovan Michael Patrick · CIK 0001653918 · VP Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,221

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-24-000044 · wk-form4_1711416165.xml · nonDerivative · entry 2

Donovan Michael Patrick · CIK 0001653918 · VP Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,992

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-24-000051 · wk-form4_1711417407.xml · derivative · entry 9

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,975 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F6 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F6 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-24-000051 · wk-form4_1711417407.xml · derivative · entry 8

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-24-000051 · wk-form4_1711417407.xml · derivative · entry 7

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,847

Underlying: Common Stock · 84,847 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-24-000051 · wk-form4_1711417407.xml · nonDerivative · entry 5

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,146,954

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2024 ..

SEC source: 0000805928-24-000051 · wk-form4_1711417407.xml · nonDerivative · entry 3

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,137,065

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2024 ..

SEC source: 0000805928-24-000051 · wk-form4_1711417407.xml · nonDerivative · entry 1

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,157,593

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2024 ..

SEC source: 0000805928-24-000049 · wk-form4_1711417219.xml · derivative · entry 9

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,725

Underlying: Common Stock · 12,725 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F6 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F6 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-24-000049 · wk-form4_1711417219.xml · derivative · entry 8

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,950

Underlying: Common Stock · 2,950 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date.

F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-24-000049 · wk-form4_1711417219.xml · derivative · entry 7

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022, 25% of the aggregate shares vest on March 16, 2023, and 25% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date.

F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022, 25% of the aggregate shares vest on March 16, 2023, and 25% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-24-000049 · wk-form4_1711417219.xml · nonDerivative · entry 5

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,615

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2024.

SEC source: 0000805928-24-000049 · wk-form4_1711417219.xml · nonDerivative · entry 3

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 168,611

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2024.

SEC source: 0000805928-24-000049 · wk-form4_1711417219.xml · nonDerivative · entry 1

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 166,377

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2024.

SEC source: 0000805928-24-000047 · wk-form4_1711417017.xml · derivative · entry 9

Scopelianos Angelo · CIK 0001751541 · Chief R&D Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F6 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F6 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-24-000047 · wk-form4_1711417017.xml · derivative · entry 8

Scopelianos Angelo · CIK 0001751541 · Chief R&D Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,125

Underlying: Common Stock · 4,125 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date.

F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-24-000047 · wk-form4_1711417017.xml · derivative · entry 7

Scopelianos Angelo · CIK 0001751541 · Chief R&D Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,282

Underlying: Common Stock · 21,281 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-24-000047 · wk-form4_1711417017.xml · nonDerivative · entry 3

Scopelianos Angelo · CIK 0001751541 · Chief R&D Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,124

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2024.

SEC source: 0000805928-24-000047 · wk-form4_1711417017.xml · nonDerivative · entry 1

Scopelianos Angelo · CIK 0001751541 · Chief R&D Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2024.

SEC source: 0000805928-24-000044 · wk-form4_1711416165.xml · derivative · entry 9

Donovan Michael Patrick · CIK 0001653918 · VP Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,625

Underlying: Common Stock · 18,625 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock.

F6 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F6 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-24-000044 · wk-form4_1711416165.xml · derivative · entry 8

Donovan Michael Patrick · CIK 0001653918 · VP Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,950

Underlying: Common Stock · 2,950 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock.

F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date.

F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-24-000044 · wk-form4_1711416165.xml · derivative · entry 7

Donovan Michael Patrick · CIK 0001653918 · VP Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock.

F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-24-000044 · wk-form4_1711416165.xml · nonDerivative · entry 5

Donovan Michael Patrick · CIK 0001653918 · VP Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,846

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2024.

SEC source: 0000805928-24-000044 · wk-form4_1711416165.xml · nonDerivative · entry 3

Donovan Michael Patrick · CIK 0001653918 · VP Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,942

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2024.

SEC source: 0000805928-24-000044 · wk-form4_1711416165.xml · nonDerivative · entry 1

Donovan Michael Patrick · CIK 0001653918 · VP Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,708

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2024.

SEC source: 0000805928-24-000041 · wk-form4_1709937172.xml · nonDerivative · entry 1

Donovan Michael Patrick · CIK 0001653918 · VP Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,708

F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $8.74 to $8.99 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-24-000039 · wk-form4_1709937069.xml · nonDerivative · entry 1

Freitag Gregory Gene · CIK 0001492710 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 271,594

F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $8.95 to $9.00 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-24-000031 · wk-form4_1709674382.xml · nonDerivative · entry 1

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 163,377

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

SEC source: 0001209191-24-003890 · doc4.xml · derivative · entry 1

Kemp Jens · CIK 0002007485 · Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,600

Underlying: Common Stock · 68,600 shares

Expires not disclosed

F1 · derivative.exercise_price: Represents the performance stock units ("PSUs") granted to the reporting person pursuant to the Issuer's Amended and Restated 2019 Long-Term Incentive Plan ("Plan") in respect of calendar year 2024. Each PSU represents the right to receive one share of Common Stock. PSUs will be eligible to be earned by the reporting person based on achievement with respect to an annualized absolute total shareholder return performance goal over a three-year performance period beginning February 22, 2024 and ending February 22, 2027, subject to the reporting person's continuous service through the end of such performance period. The number of PSUs indicated reflects the "target" number of PSUs granted to the reporting person and subject to availability under the Plan, the number of PSUs earned could range from 0% to 200% of such target number.

F1 · derivative.exercise_date: Represents the performance stock units ("PSUs") granted to the reporting person pursuant to the Issuer's Amended and Restated 2019 Long-Term Incentive Plan ("Plan") in respect of calendar year 2024. Each PSU represents the right to receive one share of Common Stock. PSUs will be eligible to be earned by the reporting person based on achievement with respect to an annualized absolute total shareholder return performance goal over a three-year performance period beginning February 22, 2024 and ending February 22, 2027, subject to the reporting person's continuous service through the end of such performance period. The number of PSUs indicated reflects the "target" number of PSUs granted to the reporting person and subject to availability under the Plan, the number of PSUs earned could range from 0% to 200% of such target number.

F1 · derivative.expiration_date: Represents the performance stock units ("PSUs") granted to the reporting person pursuant to the Issuer's Amended and Restated 2019 Long-Term Incentive Plan ("Plan") in respect of calendar year 2024. Each PSU represents the right to receive one share of Common Stock. PSUs will be eligible to be earned by the reporting person based on achievement with respect to an annualized absolute total shareholder return performance goal over a three-year performance period beginning February 22, 2024 and ending February 22, 2027, subject to the reporting person's continuous service through the end of such performance period. The number of PSUs indicated reflects the "target" number of PSUs granted to the reporting person and subject to availability under the Plan, the number of PSUs earned could range from 0% to 200% of such target number.

SEC source: 0001209191-24-003889 · doc4.xml · derivative · entry 1

DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,600

Underlying: Common Stock · 68,600 shares

Expires not disclosed

F1 · derivative.exercise_price: Represents the performance stock units ("PSUs") granted to the reporting person pursuant to the Issuer's Amended and Restated 2019 Long-Term Incentive Plan ("Plan") in respect of calendar year 2024. Each PSU represents the right to receive one share of Common Stock. PSUs will be eligible to be earned by the reporting person based on achievement with respect to an annualized absolute total shareholder return performance goal over a three-year performance period beginning February 22, 2024 and ending February 22, 2027, subject to the reporting person's continuous service through the end of such performance period. The number of PSUs indicated reflects the "target" number of PSUs granted to the reporting person and subject to availability under the Plan, the number of PSUs earned could range from 0% to 200% of such target number.

F1 · derivative.exercise_date: Represents the performance stock units ("PSUs") granted to the reporting person pursuant to the Issuer's Amended and Restated 2019 Long-Term Incentive Plan ("Plan") in respect of calendar year 2024. Each PSU represents the right to receive one share of Common Stock. PSUs will be eligible to be earned by the reporting person based on achievement with respect to an annualized absolute total shareholder return performance goal over a three-year performance period beginning February 22, 2024 and ending February 22, 2027, subject to the reporting person's continuous service through the end of such performance period. The number of PSUs indicated reflects the "target" number of PSUs granted to the reporting person and subject to availability under the Plan, the number of PSUs earned could range from 0% to 200% of such target number.

F1 · derivative.expiration_date: Represents the performance stock units ("PSUs") granted to the reporting person pursuant to the Issuer's Amended and Restated 2019 Long-Term Incentive Plan ("Plan") in respect of calendar year 2024. Each PSU represents the right to receive one share of Common Stock. PSUs will be eligible to be earned by the reporting person based on achievement with respect to an annualized absolute total shareholder return performance goal over a three-year performance period beginning February 22, 2024 and ending February 22, 2027, subject to the reporting person's continuous service through the end of such performance period. The number of PSUs indicated reflects the "target" number of PSUs granted to the reporting person and subject to availability under the Plan, the number of PSUs earned could range from 0% to 200% of such target number.

SEC source: 0001209191-24-003887 · doc4.xml · derivative · entry 1

Began Marc A · CIK 0001821352 · EVP and General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,600

Underlying: Common Stock · 68,600 shares

Expires not disclosed

F1 · derivative.exercise_price: Represents the performance stock units ("PSUs") granted to the reporting person pursuant to the Issuer's Amended and Restated 2019 Long-Term Incentive Plan ("Plan") in respect of calendar year 2024. Each PSU represents the right to receive one share of Common Stock. PSUs will be eligible to be earned by the reporting person based on achievement with respect to an annualized absolute total shareholder return performance goal over a three-year performance period beginning February 22, 2024 and ending February 22, 2027, subject to the reporting person's continuous service through the end of such performance period. The number of PSUs indicated reflects the "target" number of PSUs granted to the reporting person and subject to availability under the Plan, the number of PSUs earned could range from 0% to 200% of such target number.

F1 · derivative.exercise_date: Represents the performance stock units ("PSUs") granted to the reporting person pursuant to the Issuer's Amended and Restated 2019 Long-Term Incentive Plan ("Plan") in respect of calendar year 2024. Each PSU represents the right to receive one share of Common Stock. PSUs will be eligible to be earned by the reporting person based on achievement with respect to an annualized absolute total shareholder return performance goal over a three-year performance period beginning February 22, 2024 and ending February 22, 2027, subject to the reporting person's continuous service through the end of such performance period. The number of PSUs indicated reflects the "target" number of PSUs granted to the reporting person and subject to availability under the Plan, the number of PSUs earned could range from 0% to 200% of such target number.

F1 · derivative.expiration_date: Represents the performance stock units ("PSUs") granted to the reporting person pursuant to the Issuer's Amended and Restated 2019 Long-Term Incentive Plan ("Plan") in respect of calendar year 2024. Each PSU represents the right to receive one share of Common Stock. PSUs will be eligible to be earned by the reporting person based on achievement with respect to an annualized absolute total shareholder return performance goal over a three-year performance period beginning February 22, 2024 and ending February 22, 2027, subject to the reporting person's continuous service through the end of such performance period. The number of PSUs indicated reflects the "target" number of PSUs granted to the reporting person and subject to availability under the Plan, the number of PSUs earned could range from 0% to 200% of such target number.

SEC source: 0000805928-24-000009 · wk-form4_1704408521.xml · nonDerivative · entry 1

Naor Nir · CIK 0001982278 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

SEC source: 0000805928-24-000020 · wk-form4_1705011234.xml · derivative · entry 1

Weiler Kathy Johnson · CIK 0001979466 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,476

Underlying: Common Stock · 65,476 shares

Expires 2033-12-20

F1 · derivative.exercise_date: Option grant for joining the Issuer's Board of Directors. Options vest in three equal annual installments on the annual anniversary of the grant date with the first vesting date occurring on December 20, 2024.

SEC source: 0000805928-23-000153 · wk-form4_1702501633.xml · nonDerivative · entry 3

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,603

SEC source: 0000805928-23-000153 · wk-form4_1702501633.xml · nonDerivative · entry 2

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,573

SEC source: 0000805928-23-000153 · wk-form4_1702501633.xml · nonDerivative · entry 1

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,693

SEC source: 0000805928-23-000141 · wk-form4_1697243414.xml · nonDerivative · entry 2

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,103

F2 · shares: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the PSUs and does not represent an open market sale.

SEC source: 0000805928-23-000140 · wk-form4_1697243379.xml · nonDerivative · entry 2

DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,377

F2 · shares: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the PSUs and does not represent an open market sale.

SEC source: 0000805928-23-000139 · wk-form4_1697243344.xml · nonDerivative · entry 2

Donovan Michael Patrick · CIK 0001653918 · VP Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,018

F2 · shares: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the PSUs and does not represent an open market sale.

SEC source: 0000805928-23-000138 · wk-form4_1697243312.xml · nonDerivative · entry 2

Scopelianos Angelo · CIK 0001751541 · Chief R&D Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,969

F2 · shares: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the PSUs and does not represent an open market sale.

SEC source: 0000805928-23-000136 · wk-form4_1697243269.xml · nonDerivative · entry 2

MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,476

F2 · shares: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the PSUs and does not represent an open market sale.

SEC source: 0000805928-23-000124 · wf-form4_169420440642854.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,342

SEC source: 0000805928-23-000122 · wf-form4_169408287703094.xml · derivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,904

Underlying: Common Stock · 11,904 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting.

F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting.

SEC source: 0000805928-23-000122 · wf-form4_169408287703094.xml · derivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,436

Underlying: Common Stock · 20,436 shares

Expires 2033-09-01

F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting.